Company Profile
Cloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company researches and develops ophthalmic drugs for chronic eye diseases. The company develops CBT-001, which is in Phase 3 clinical trial for treating pterygium.
Its portfolio also includes CBT-009, a topical formulation of atropine that is in Phase 1/2 study indicated for the treatment of juvenile myopia, CBT-004, a VEGF receptor inhibitor, which is in Phase 2 clinical trial for treating vascularised pinguecula, and CBT-006, a cholesterol dissolving molecule containing the active pharmaceutical ingredient of hydroxypropyl beta-cyclodextrins that is in Phase 2 clinical trial for the treatment of meibomian gland dysfunction associated dry eye disease.
It also develops CBT-199 and CBT-145 for the treatment of presbyopia, a condition caused by an age-related process. Its portfolio also includes CBT-007, an eye drop for enhancing success rate of glaucoma filtration surgery, and CBT-011, an antibody-drug-synergism conjugate for the treatment of diabetic macular edema. Founded in 2015, the company is headquartered in Irvine, California.